Simtuzumab Drug Fails Mid-Study
Gilead Sciences Inc. has stated that its experimental drug used for improving the lifespan of patients with pancreatic cancer has failed a mid-stage clinical trial.
About the Mid-Study Failure
According to Medscape, the experimental drug, simtuzumab, did not significantly improve how long patients diagnosed with pancreatic cancer live without their disease worsening. The study failed in its main goal of improving progression-free-survival (PFS). More details of the study can be found below.
Simtuzumab is also being tested for use in colorectal cancer, myelofibrosis, idiopathic pulmonary fibrosis, and liver fibrosis.
Description of the Simtuzumab Study
- The study evaluated simtuzumab (in combination with chemotherapy) against a placebo (plus chemotherapy) in previously untreated patients with advanced pancreatic cancer.
- There was no statistically significant difference in PFS between patients on simtuzumab and those on the placebo.